In the case of cancers, plenty of studies have recently demonstrated that RIPK1 plays a critical role in cancer immune checkpoint blockade (ICB) by modulating inflammation or immunity-related signaling pathway [12–14]. This evidence concerns the gene RIPK1 and cancer.